Reported 2 days ago
Viking Therapeutics' stock has seen a significant decline of 68% since its 2024 peak due to concerns about manufacturing costs for its anti-obesity drug VK2735. Despite the downturn, historical trends in biopharma suggest that such volatility can precede recoveries, especially as the drug moves closer to FDA approval. With high market potential for weight-loss drugs, there may be a buying opportunity for investors willing to wait for patient growth, as the company continues its clinical trials.
Source: YAHOO